Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    ESGTI

    MCap

    CHF25m

    Last close

    CHF0.97

    ▲ 0.52 (115.56%)

    MagForce

    MCap

    —

    Last close

    -0.02

    ▲ 0.01 (100.00%)

    DFR Gold

    MCap

    CAD15m

    Last close

    CAD0.10

    ▲ 0.03 (42.86%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

BiondVax – executive interview

BiondVax – executive interview

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercialising innovative products for the prevention and treatment of infectious diseases and other illnesses. It is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases such as COVID-19, asthma and psoriasis.

In this interview, Dr Tamar Ben-Yedidia, BiondVax’s chief science officer, discusses the company’s current strategy, the progress made with its NanoAb pipeline and forthcoming milestones.

< Previous
Next >

You may also be interested in these:

Investment Companies

Riverstone Credit Opportunities Income - executive interview

Consumer

ForFarmers – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free